Hosted on MSN1mon
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?myChoiceCDx Progresses Well: Myriad Genetics' FDA-approved tumor test determines HRD status in patients with ovarian cancer. Earlier, the company had announced plans to expand the test to other ...
Hosted on MSN1mon
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?Last month, Myriad Genetics announced that its Genomic Instability Score (“GIS”) to determine Homologous Recombination Deficiency (“HRD”) will be reported for all samples analyzed with ...
KUALA LUMPUR, June 12 (Bernama) -- Myriad Genetics Inc announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade ...
underscore its commitment to improving access to HRD diagnostic testing. Yet, a volatile macroeconomic situation and competitive disadvantages may hurt Myriad Genetics’ operations. In the past ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback